This database contains 472 studies, archived under the term: "Pharmaceutical Interventions"
Click here to filter this large number of results.
Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial
Quinn, Joseph F.,
Raman, Rema,
Thomas, Ronald G.,
Yurko-Mauro, Karin,
Nelson, Edward B.,
van Dyck, Christopher,
Galvin, James E.,
Emond, Jennifer,
Jack, Clifford R., Jr.,
Weiner, Michael,
Shinto, Lynne,
Aisen, Paul S
Context: Docosahexaenoic acid (DHA) is the most abundant long-chain polyunsaturated fatty acid in the brain. Epidemiological studies suggest that consumption of DHA is associated with a reduced incidence of Alzheimer disease. Animal studies demonstrate that oral intake of DHA reduces Alzheimer-like brain pathology.; Objective: To determine if supplementation with DHA slows cognitive and functional decline […]
Increased glutamate in the hippocampus after galantamine treatment for Alzheimer disease
Penner, Jacob,
Rupsingh, Raul,
Smith, Matthew,
Wells, Jennie L.,
Borrie, Michael J.,
Bartha, Robert
Galantamine is a cholinesterase inhibitor and allosteric potentiating ligand modulating presynaptic nicotinic acetylcholine receptors that is used in the treatment of Alzheimer disease (AD). The purpose of this study was to determine if galantamine treatment would result in detectable hippocampal metabolite changes that correlated with changes in cognition, as measured by the Mini-Mental State Examination […]
Persistence of the effects of Cerebrolysin on cognition and qEEG slowing in vascular dementia patients: results of a 3-month extension study
Muresanu, Dafin F.,
Alvarez, X. Anton,
Moessler, Herbert,
Novak, Philipp H.,
Stan, Adina,
Buzoianu, Anca,
Bajenaru, Ovidiu,
Popescu, Bogdan O.
The maintenance of the effects of Cerebrolysin, a peptidergic compound with neurotrophic activity, on cognitive performance and qEEG activity was investigated through a 12-week, open-label extension of a 4-week, randomised, placebo-controlled pilot study. Thirty-three out of 41 patients with mild-to-moderate severe probable vascular dementia (VaD) according to NINDS-AIREN participating in the double-blind phase of the […]
Short-term effect of combined drug therapy and cognitive stimulation therapy on the cognitive function of Alzheimer’s disease
Matsuda, Osamu,
Shido, Emi,
Hashikai, Ayako,
Shibuya, Haruka,
Kouno, Mitsue,
Hara, Chizuko,
Saito, Masahiko
Background: Acetylcholinesterase inhibitors (i.e. donepezil) are known to benefit Alzheimer’s disease (AD) patients. However, the combined effects of acetylcholinesterase and cognitive stimulation therapy (CST) are still debated. The present study examined their combined effects on the progression of cognitive decline in AD.; Methods: The present study was a non-randomized controlled study and included two groups […]
Effects of rivastigmine on common symptomatology of Alzheimer’s disease (EXPLORE)
Objective: To evaluate, in a real-world clinical setting, the efficacy of rivastigmine in the management of six symptoms commonly associated with Alzheimer’s disease (AD).; Methods: This was a naturalistic, prospective, open-label, multi-centre, post-marketing, observational study. Data were collected by the participating study physicians at their practices across Canada. Subjects had a clinical diagnosis of mild-to-moderate […]
Comparative cardiovascular safety of dementia medications: a cross-national study
Fosbøl, Emil L.,
Peterson, Eric D.,
Holm, Ellen,
Gislason, Gunnar H.,
Zhang, Yinghong,
Curtis, Lesley H.,
Køber, Lars,
Iwata, Isao,
Torp-Pedersen, Christian,
Setoguchi, Soko
Objectives: To compare the cardiovascular safety of currently marketed dementia medications in new users in the United States and Denmark.; Design: Retrospective cohort study.; Setting: Nationally representative sample of Medicare beneficiaries from 2006 through 2009 and nationwide Danish administrative registries from 1997 through 2007.; Participants: Individuals treated with a dementia medication aged 65 and older.; […]
Effect of CYP2D6*10 and APOE polymorphisms on the efficacy of donepezil in patients with Alzheimer’s disease
Zhong, Yuan,
Zheng, Xueli,
Miao, Ya,
Wan, Lili,
Yan, Hong,
Wang, Beiyun
Background: The aim of this study was to evaluate the effect of CYP2D6*10 and APOE polymorphisms on both steady-state plasma concentrations (Cp) and clinical response of donepezil in patients with mild-to-moderate Alzheimer’s disease (AD).; Methods: A total of 110 Chinese AD patients participated in this study. Patients were treated with 5 to 10 mg of […]
Clinical observation on effect of scalp electroacupuncture for mild cognitive impairment
Zhang, Hong,
Zhao, Ling,
Yang, Sha,
Chen, Zhigang,
Li, Yingkun,
Peng, Xiaohong,
Yang, Yulong,
Zhu, Manjia
Objective: To evaluate the therapeutic effect of scalp electroacupuncture for mild cognitive impairment (MCI) in the early stage.; Methods: Two hundred and thirty three MCI patients were randomly divided into three groups: the drug group, the scalp electroacupuncture group, and the syndrome differentiation group. For the scalp electroacupuncture group, the points of Baihui (DU 20), […]
Effects of memantine on clinical ratings, fluorodeoxyglucose positron emission tomography measurements, and cerebrospinal fluid assays in patients with moderate to severe Alzheimer dementia: a 24-week, randomized, clinical trial
Wang, Tao,
Huang, Qiu,
Reiman, Eric M.,
Chen, Kewei,
Li, Xia,
Li, Guanjun,
Lin, Zhiguang,
Li, Chunbo,
Xiao, Shifu
Most experts consider that memantine has a symptomatic treatment, but clinical trials have not yet provided compelling evidence to support a disease-modifying effect. We investigate the effects of memantine on clinical ratings; fluorodeoxyglucose positron emission tomography (FDG-PET) measurements, which can monitor disease-modifying effect; and cerebrospinal fluid (CSF) assays in patients with moderate to severe probable […]